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Abstract: A combined chemo-enzymatic synthesis/NMR-
based methodology is presented to identify, in unambiguous
manner, the distinctive binding epitope within repeating sugar
oligomers when binding to protein receptors. The concept is
based on the incorporation of 13C-labels at specific mono-
saccharide units, selected within a repeating glycan oligomeric
structure. No new chemical tags are added, and thus the
chemical entity remains the same, while the presence of the 13C-
labeled monosaccharide breaks the NMR chemical shift
degeneracy that occurs in the non-labeled compound and
allows the unique identification of the different components of
the oligomer. The approach is demonstrated by a proof-of-
concept study dealing with the interaction of a polylactosamine
hexasaccharide with five different galectins that display distinct
preferences for these entities.
Introduction
Repeating-sugar sequences to form extended oligosac-
charides and polysaccharides are ubiquitous among living
organisms. These elongated structures can interact with
carbohydrate-specific antibodies[1] or glycan binding pro-
teins[2] to mediate diverse biological events.[3] From a supra-
molecular chemistry perspective, the oligo- or polymeric
glycan pattern is thought to increase the avidity (and thus
apparent affinity) of these binding processes that are other-
wise weak.[4] Understanding the mechanisms that regulate
such multivalent interactions at the molecular level, and the
resulting consequences in terms of binding affinity and
selectivity, represents a challenging task, usually hampered
by the difficulty in deconvoluting the single contributions of
each of the repeating units to the global binding event.
Poly-N-acetyllactosamine (poly-LacNAc), which is
a chemical structure present on many mammalian glycans, is
composed of repeating units of the disaccharide N-acetyllac-
tosamine (LacNAc, Galb1-4GlcNAcb). These extensions are
commonly found on glycolipids and glycoproteins,[5] where
their presence has been associated to key biological processes,
especially related to immune response regulation.[6] Poly-
LacNAc extensions serve as elongated scaffolds for the
presentation of specific epitopes (such as ABO, Lewis or
HNK-1 antigens, sialic acid or keratan sulfate)[7] for their
interaction with specific receptors, but they are also binding
epitopes themselves, acting as ligands for a family of
endogenous lectins,[8] the galectins.
This lectin family, widely distributed in animals, comprises
15 different members in humans that are associated with
a remarkable number of pathological phenomena, mostly
related to immunity,[9] cancer[10] and autoimmune disorders.[11]
All galectins share the ability to bind LacNAc. Structural
modifications of this common epitope, including its sequential
repetition into poly-LacNAc chains, modulate the affinity and
selectivity for the different galectins.[12, 13] In fact, different
binding mechanisms and preferences are expected for each
galectin towards poly-LacNAc chains.[16] These associations
become particularly significant on cell surfaces, where they
give rise to the so-called galectin lattice,[14] which impacts cell
surface dynamics and regulates receptor localization and
signaling.[15] Studies of the differential binding preferences of
galectins for poly-LacNAc have yielded somehow conflicting
results. The discrepancies have been interpreted[16] in terms of
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the intrinsic differences of the various techniques employed in
each study, which ultimately reflect the unique binding mode
of each galectin. Indeed, an additional level of regulation
operating in galectin-mediated binding events is provided by
the multivalent nature of galectins, which leads to different
binding outcomes when surface-bound ligands versus in
solution are compared.[16]
Galectins are classified into three different groups de-
pending on the organization of their Carbohydrate Recog-
nition Domains (CRDs). Prototype galectins, which include
Galectins (Gal) -1, -2, -7, -10, -11, -13, -14 and -15, are non-
covalent homodimers with two identical CRDs; tandem
repeat galectins, including Gal-4, -6, -8, -9 and -12, are
heterodimers containing two different CRDs covalently
linked through a short peptide; while Gal-3, the only member
of the chimera type, features a single CRD with a long peptide
chain through which it forms oligomers of different size. It is
nowadays assumed that Gal-3, the C-terminal domain of Gal-
8 (Gal-8C), and both the C- and N-terminal domains of Gal-9
(Gal-9C and Gal-9N) preferentially bind internal LacNAc
units, thus acting as endo-type lectins, while Gal-1, Gal-2, Gal-
7 and the N-terminal domain of Gal-8 (Gal-8N) prefer
terminal positions, thus acting as exo-type lectins.[2] These
conclusions have been based on macroscopic-type biological/
biochemical assays and, to the best of our knowledge, no
unambiguous experimental evidence has been yet presented
for some of these systems and the structural basis for
selectivity remains elusive. When multiple poly-LacNAc
chains are installed into glycoconjugates, as part of branched
N- and O-glycans, understanding how these extensions affect
galectin binding becomes a challenging endeavor.[17, 18]
Herein, an NMR-based approach to easily identify the
preferred binding epitope within repeating oligomeric glycans
when binding to protein receptors is presented. It is based on
the incorporation of 13C-labels in selected monosaccharide
units within a repeating glycan oligomer. Thus, the chemical
entity remains the same, but the 13C-label breaks the NMR
chemical shift degeneracy that occurs in the non-labeled
compound. Therefore, ligand-based NMR strategies can be
employed to report on the specific binding epitopes. The
introduction of selective 13C-labels into carbohydrate oligo-
mers has been reported for a linear hexamer of b1-6 linked
glucose,[19] providing structural and conformational informa-
tion otherwise not accessible.
Herein, 13C-labels have been introduced at specific
positions of a poly-LacNAc fragment composed of three
repeating LacNAc units (tri-LaNAc). The study of their
specific interaction with a panel of galectins was carried out
by 2D STD-1H,13C-HSQC NMR experiments,[20] which re-
vealed the precise preference of each galectin for a specific
LacNAc unit. Previously, the enzymatic synthesis of di- and
tri-LacNAc oligosaccharides with 13C-galactose enrichment
has been reported[21] to monitor Gal-1 binding through 1H-
line broadening effects. Herein, we describe the enzymatic
synthesis of hexasaccharides composed of three LacNAc units
(tri-LacNAc) with uniformly 13C-labeled-galactose (UL-13C6-
galactose) units introduced at selected positions. The com-
plementary UL-13C6-galactose labeling Scheme (Scheme 1)
permitted to distinguish the individual contribution of each
LacNAc moiety to tri-LacNAc binding by different galectins.
Results and Discussion
Three tri-LacNAc hexasaccharide were obtained with
different labeling: 5 a with all the three-galactose residues 13C-
labeled, and two tri-LacNAc hexasaccharides, with a single-
galactose 13C-labeled at either the middle (5 b) or the
reducing-end (5c). Tetrasaccharides 3 (3a, 3b and 3c) were
straightforward prepared by the subsequent treatment of
commercial N-acetyllactosamine 1 b and 1a with b1,3-N-
acetylglucosaminyltransferase (HP-39) in the presence of
uridine-5’-diphospho (UDP)-N-acetyl-glucosamine
(GlcNAc) and then with b1,4-galactosyltransferase (LgtB)
and UDP-galactose or UDP-UL-13C6-galactose, respectively.
Repeated action with HP-39 and LgtB installed a third
modified LacNAc motif to furnish the target hexasaccharides
5 (5a, 5b and 5c) (Figure 1).[22, 23]
In this study, five galectins (or galectin domains) from all
three families were selected to be interrogated about their
binding preferences toward poly-LacNAc structures: (i) two
Scheme 1. Left. The typical N-glycan structure containing one poly-
LacNAc chain at the a6 branch. Right. The tri-LacNAc oligomers
containing selective 13C-C6-galactose labeling, synthesized and em-
ployed in this study.
Figure 1. Synthesis of tri-LacNAc compounds 5a, 5b and 5c with
different 13C-labeling schemes. Reagents and conditions: a) HP-39,
UDP-GlcNAc; b) LgtB, UDP-UL-13C6-galactose; c) LgtB, UDP-galactose.
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homodimeric prototype galectins, Gal-1 and Gal-7, (ii) the
CRD of the chimera-type Gal-3 (Gal-3 CRD), and (iii) the
full length tandem-repeat Gal-8 (Gal-8 FL) were used, along
with the N-terminal domain of Gal-9 (Gal-9N), for which X-
ray crystallographic structures have been obtained in complex
with a tri-LacNAc fragment.[24] All galectins were obtained
through E. coli overexpression and purified as described in
the Supporting Information.
Binding of the differently labeled tri-LacNAc compounds
(5a, 5b, 5c) to the selected galectins was monitored through
2D STD-1H,13C-HSQC NMR experiments. Conventional 1D
1H-STD NMR experiments have been extensively used to
study the recognition of b-galactose containing glycans by
galectins,[25, 26] whereby the strongest STD effect systemati-
cally corresponds to protons H6, H5 and H4 of the b-galactose
residue, central element in these binding events, providing
most of the intermolecular interactions, including a key CH-p
stacking with a conserved tryptophan (Trp) residue at the
galectin binding site.[27, 28]
In the regular HSQC spectrum of the tri-labeled com-
pound 5a (Figure 2 and SI), the cross-peaks for C2, C3, C4
and C5 of the B and C b-galactose residues resonate at
identical positions, while those for residue A display clearly
differentiated cross-peaks. On the contrary, the signals for C1
(anomeric) and C6 were indistinguishable for all the three b-
galactose A, B and C residues. Thus, this compound permits
a straightforward discrimination of the binding preference of
the different galectins for the terminal (A) versus non-
terminal b-galactose residues (B and C), just by observing the
relative STDs of the different signals (C2-H2, C3-H3, C4-H4
and C5-H5) in the 2D STD-1H,13C -HSQC spectra. This is
shown in Figure 2, where the 2D STD-1H,13C -HSQC spectra
for the interaction of tri-LacNAc 5a with the 5 galectins are
shown in panel A. The analysis of the individual STD spectra
and the epitope mapping for each galectin is shown in
Figure S14. Remarkably, for all spectra, within every b-
galactose residue, the signal showing the strongest STD effect
is consistently that of the C5-H5, followed by that of C4-H4,
and finally C3-H3 and C2-H2, in agreement with the expected
binding mode described above. To facilitate the comparison
among all systems, the STD values (in %) of all the signals
corresponding to the A residue were added and compared to
the sum of the STDs corresponding to residues B and C,
which are indistinguishable (Figure 2B). The conclusions
about the terminal versus non-terminal epitope binding
preferences of the five galectins can be easily drawn from
Figure 2. Gal-1 is the only galectin that shows specificity for
the terminal LacNAc, while the binding of the other prototype
galectin, Gal-7 is not exclusive for the terminal epitope. In
contrast, chimera type Gal-3 CRD and the N-terminal
domain of tandem repeat type Gal-9 preferentially recognize
non-terminal LacNAc epitopes, while the likewise tandem
repeat Gal-8 does not discriminate between terminal and non-
terminal LacNAc moieties.
Next, to further distinguish binding preferences for the
reducing-end (residue C) versus internal (residue B) LacNAc
Figure 2. (A) 2D STD-1H,13C-HSQC NMR spectra of tri-LacNAc 5a (with 13C6-labeled-galactose at residues A, B and C) in the presence of Gal-1,
Gal-3 CRD, Gal-7, Gal-8 FL, and Gal-9N (ligand:galectin molar ratios are 30:1). Left, 2D 1H,13C-HSQC spectrum with signal assignment and right,
2D STD-1H,13C-HSQC NMR spectra. (B) Corresponding sum of STD effects (in percent) for all signals of the terminal galactose A (blue) and the
two spectrally indistinguishable residues B and C (gray). The STD sum was computed from the net signal integrals in the 2D 1H,13C-HSQC
spectrum with on-resonant protein saturation (2 s at 0.84 ppm using a train of 33 ms PC9_4 908 pulses) vs. off-resonant irradiation (at
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units, compounds 5c and 5b, with a single 13C6-labeled-
galactose moiety in the corresponding positions, were em-
ployed. The 2D STD-1H,13C-HSQC spectra are shown in the
SI. In this case, all the signals in each spectrum correspond
unambiguously to the only labeled b-galactose residue in each
case: B in compound 5b and C in compound 5c. The analysis
of the STD values determined for all the cross-peaks in the
2D STD-1H,13C-HSQC spectra of 5 b and 5c with the different
galectins is shown in Figure 3. Remarkably, prototype Gal-
1 showed absence of any STD effects, evidencing no
recognition of either internal or reducing-end b-galactose
residues. The fact that the 2D STD-1H,13C-HSQC spectrum
with the tri-labeled analogue (5 a) did showed detectable,
although very weak, STD signal for these non-terminal
positions (Figure 2 A) could be explained by a very weak
interaction, below the detection limit in the experiments with
compounds 5b and 5 c, but observable with 5a where the
cross-peaks display double intensity with respect to those in
the mono-labeled compounds.
For all the other galectins, the 2D STD-1H,13C-HSQC
spectra for 5b and 5c showed STD signals, and for all of them
except for Gal-3 CRD, the STD intensities were always
stronger for 5b than for 5 c. This fact demonstrates that,
although both b-galactose residues at positions B and C are
binding epitopes, the binding through the reducing-end
LacNAc (C) is much weaker than through the middle
LacNAc (B) epitope. This difference is less pronounced for
tandem-repeat Gal-8 for which the STD for residue B is only
2-fold stronger than that for residue C, and not the case for
Gal-3 CRD, which binds B and C epitopes equally.
Besides yielding residue-specific information, the strategy
described herein also affords atomic-specific information,
providing molecular details of the complexes. For 5b and 5c,
the STD values for all the CH correlations of the bound
galactose residue were available. The corresponding informa-
tion was not available for 5a, given the overlapping for the
galactose H6s for all the three LacNAc units. The obtained
STD profiles for each b-galactose with the different galectins
(Figure 3) were very similar, showing a general trend where
the strongest STD effect is experienced by position 5 of the
galactose residue, which basically agrees with the known
binding modes for the reported complexes between galectins
and Lac/LacNAc-containing molecules complexes. Interest-
ingly, minor differences were found for the Gal-7/5 b complex,
where the strongest STD corresponded instead to position 6.
This minor difference could be indicative of subtle differences
in the binding pose. Thus, the deposited X-ray crystallo-
graphic structures of the complexes formed between LacNAc
and Gal-3, Gal-9N and Gal-7 were compared, showing that
the tilt of the galactopyranose ring with respect to the
conserved Trp residue at the binding site is slightly different in
the complex with Gal-7 to those of Gal-3 and Gal-9N
(Figure S16), thus providing a possible explanation of the
STD NMR experimental observations
For the interaction of Gal-3 with 5 a, the HSQC (Fig-
ure S15) and 2D STD-1H,13C-HSQC spectrum (Figure S10)
showed a new set of weak cross-peaks. A 13C-decoupled-
ROESY spectrum (Figure S15) confirmed that they corre-
spond to the bound ligand form, as deduced from their
chemical exchange cross-peaks with the signals of B + C Gal
residues in the free form. Gal-3 has the strongest binding
affinity for a single LacNAc unit (KD = 53 mM)
[25] among the
galectins studied herein. We have previously reported the
detection of the galectin-bound ligand NMR signals;[25,29]
however, this is generally difficult to achieve given the typical
low affinity interactions. Herein, the 13C-labeling provides the
impetus to deduce exquisite structural information of the
ligand in the bound form.[30] In this case, all CH signals of the
b-galactose were shifted up-field due to the sugar-aromatic
CH-p stacking interaction, being the extent of the shift
proportional to the distance of the CH to the conserved
galectin Trp (W168 in Gal-3 CRD) residue in the binding
site.[25]
Conclusion
Poly- and oligo-meric glycans, composed of repeating
(mono- or oligo-) saccharide units, such as polysialic acid,
polylactosamine, glucan, chitin, glycosaminoglycans, capsular
polysaccharides, etc…, are ubiquitous structures in Nature.
Although NMR is one of the best suited techniques to provide
atomic detailed information on their recognition by protein
receptors, the NMR chemical shift degeneracy occurring in
Figure 3. Analysis of 2D STD-1H,13C-HSQC NMR experiments for 5b
and 5c with the different galectins. The plots represent the STD
intensity in % ((cross-peak integral in the STD spectrum/cross-peak
intensity in the reference spectrum) W 100) of every CH cross-peak of
the galactose residue (represented in the X axis). Pertaining 2D STD-
1H,13C-HSQC NMR spectra were recorded as detailed in Figure 2.
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homo-oligomers significantly limits the profundity of the
analysis. Herein, the introduction, of 13C-labels at selected
positions permits to pinpoint the specific glycan binding
epitopes in a repeating glycan oligomer sequence.
As proof-of-concept, the proposed approach has been
applied to examine the binding preferences of various
galectins for poly-LacNAc sequences. As expected,[12, 13, 31,32]
Gal-1 showed specificity for the terminal LacNAc epitope,
while Gal-3 CRD exhibited the full opposite preference. Gal-
7 also displayed preference for the terminal position, although
with less selectivity than Gal-1. In fact, this lectin also binds
the internal LacNAc (B) epitope, with only slightly lower
affinity than the terminal one, while the affinity was
drastically reduced (Figure 2 & Figure 3) for the reducing-
end LacNAc (C). This is an interesting result considering that
previous studies on Gal-7 binding to poly-LacNAc had shown
little or even no effect on the affinity depending on the
number of LacNAc units.[12, 32] Gal-9N showed similar prefer-
ences to Gal-3 CRD, with almost no interaction with the
terminal (A) epitope. While this was expected for Gal-3, this
is an interesting result for Gal-9N, since crystals of this
domain only bound to the terminal b-galactose unit in di-
LacNAc sequences have been obtained and solved by X-ray
crystallography (pdb 2ZHK and 2ZHL).[24] Our data shows
however, that in solution, binding to the internal epitope is
clearly preferred. Finally, full-length Gal-8 showed no dis-
crimination for the different LacNAc positions.[12] Therefore,
the methodology presented herein allows answering precise
molecular recognition questions in a direct manner, pushing
the limits of applications of NMR to the analysis of complex
glycans with repetitive or multivalent presentations. Morever,
this combined specific-labeling/NMR-based approach should
also be useful beyond its application for disentangling the role
of specific residues in complex glycans. The concept can be
also adapted to study and dissect multivalent interactions in
diverse supramolecular systems that contain repetitions of the
same building block.
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